IBI 3013
Alternative Names: IBI-3013Latest Information Update: 06 May 2026
At a glance
- Originator Innovent Biologics
- Class Monoclonal antibodies
- Mechanism of Action Interleukin 15 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Alopecia areata; Vitiligo
Most Recent Events
- 18 Apr 2026 Phase-I clinical trials in Alopecia areata in China (IV) (NCT07554222)
- 18 Apr 2026 Phase-I clinical trials in Alopecia areata in China (SC) (NCT07554222)
- 18 Apr 2026 Phase-I clinical trials in Vitiligo in China (IV) (NCT07554222)